ABBVIE INC. (ABBV)
Clinical trial NCT05296447 updates: 1. phase: not set → PHASE2 2. completion date: 2028-05-01 → 2031-06-01 3. primary completion date: 2028-05-01 → 2031-06-01 4. study type: OBSERVATIONAL → INTERVENTIONAL 5. allocation: not set → NON_RANDOMIZED 6. intervention model: not set → PARALLEL 7. primary purpose: not set → TREATMENT 8. masking: not set → NONE 9. collaborators added: REGENXBIO Inc.
📉 **NEGATIVE** • Medium confidence analysis (69%) • Mild negative clinical indicator • Limited downside risk **Sentiment:** Negative (20%) **Content type:** Clinical